锌制剂联合酪酸梭菌二联活菌制剂对腹泻患儿的疗效题录

目的探讨锌制剂联合酪酸梭菌二联活菌制剂对腹泻患儿临床症状缓解时间及微炎症指标的影响。方法前瞻性随机对照试验, 选择2021年3月至2022年5月于都县妇幼保健院就诊的79例腹泻患儿, 采用随机数字表法分成对照组(40例)和试验组(39例)。对照组男22例、女18例, 月龄(21.36±4.25)个月;试验组男20例、女19例, 月龄(21.47±4.35)个月。两组均予常规治疗, 在其基础上对照组予锌制剂治疗, 试验组在常规治疗基础上予锌制剂联合酪酸梭菌二联活菌制剂治疗, 持续治疗7 d。对比两组症状缓解时间、血锌水平、免疫功能免疫球蛋白A(IgA)、IgM、IgG]、微炎症指标白细胞介素-10(IL-10)、IL-6、肿瘤坏死因子α(TNF-α)]及不良反应情况。采用t检验、χ2检验。结果治疗后, 试验组便检正常时间(5.19±1.26)d]、体温恢复时间(3.63±1.09)d]、呕吐缓解时间(1.55±0.48)d]、腹痛缓解时间(1.37±0.40)d]均短于对照组(8.35±1.51)d、(5.56±1.18)d、(3.08±0.91)d、(2.79±0.81)...

Effect of zinc preparation combined with clostridium butyricum bifunctional viable preparation in children with diarrhea

Objective　To investigate the effect of zinc preparation combined with clostridium butyricum bifunctional viable preparation on clinical symptom relief time and micro inflammation indexes in children with diarrhea. Methods　It was a prospective randomized controlled trial. A total of 79 children with diarrhea who visited Yudu Maternal and Child Health Hospital from March 2021 to May 2022 were divided into a control group (40 cases) and an experimental group (39 cases) by the random number table method. In the control group, there were 22 males and 18 females, with an age of (21.36±4.25) months old. There were 20 males and 19 females in the experimental group, with an age of (21.47±4.35) months old. Both groups were given routine treatment. On the basis of routine treatment, the control group was given zinc preparation, and the experimental group was given zinc preparation combined with clostridium butyricum bifunctional viable preparation for 7 days. The symptom relief time, blood zinc level, immune function immunoglobulin A (IgA), IgM, and IgG], micro inflammation indicators interleukin-10 (IL-10), IL-6, and tumor necrosis factor α (TNF-α)], and adverse reactions were compared between the two groups. t test and χ² test were used. Results　After treatment, the time of stool examination returning to normal (5.19±1.26) d], temperature recovery time (3.63±1.09) d], vomiting relief time (1.55±0.48) d], and abdominal pain relief time (1.37±0.40) d] of the experimental group were shorter than those of the control group (8.35±1.51) d, (5.56±1.18) d, (3.08±0.91) d, and (2.79±0.81) d], with statistically significant differences (all P<0.05). After treatment, the levels of IgA (1.80±0.55) g/L], IgM (16.08±1.24) g/L], IgG (1.63±0.51) g/L], and blood zinc (66.48±10.14) μmol/L] in the experimental group were higher than those in the control group (1.49±0.48) g/L, (14.26±1.13) g/L, (1.35±0.40) g/L, and (57.24±9.36) μmol/L], with statistically significant differences (all P<0.05). After treatment, the levels of IL-6 (14.24±3.66) ng/L] and TNF-α (1.73±0.53) mg/L] in the experimental group were lower than those in the control group (19.15±4.50) ng/L and (3.19±0.86) mg/L], and the IL-10 level (33.09±4.32) ng/L] was higher than that in the control group (26.76±3.18) ng/L], with statistically significant differences (all P<0.05). Conclusion　Zinc preparation combined with clostridium butyricum bifunctional viable preparation can regulate the blood zinc level and micro inflammatory reaction in children with diarrhea, enhance the body immunity, and accelerate the clinical symptom relief, with good safety.